Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3372993 · 3 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Remternetug | EXPERIMENTAL | Remternetug will be administered subcutaneously (SC) |
| Placebo | PLACEBO_COMPARATOR | Placebo will be administered Subcutaneously (SC) |
| LY3372993 (Part A) | EXPERIMENTAL | LY3372993 administered as multiple doses either intravenously (IV) or subcutaneously (SC). |
| LY3372993 (Part B) | EXPERIMENTAL | LY3372993 administered as single dose IV or SC. |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo administered as multiple doses IV or SC. |
| Placebo (Part B) | PLACEBO_COMPARATOR | Placebo administered as single dose IV or SC. |
| Name | Type | Description |
|---|---|---|
| LY3372993 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, electrocardiogram (ECG), and Magnetic resonance imaging (MRI). * Participants must be native Chinese. To qualify as Chinese for this stud...
Top 20 of 24 competitors
LY3372993 is an investigational small molecule being studied for Alzheimer's disease. It is also being evaluated in healthy participants to assess its safety and tolerability. The drug is in Phase 1 clinical development and is not yet approved by regulatory authorities.
LY3372993 is a small molecule being developed for Alzheimer's disease. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is currently in Phase 1 studies to evaluate its safety and how it is processed in the body.
LY3372993 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the stock exchange under the ticker symbol LLY. The drug is currently in Phase 1 clinical trials for Alzheimer's disease and in healthy participants.
LY3372993 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. All completed and ongoing trials for LY3372993 are Phase 1 studies.
LY3372993 has been studied in three Phase 1 clinical trials. Two trials, NCT03720548 and NCT04451408, are completed and enrolled participants with Alzheimer's disease and healthy volunteers in the United States and Japan. A third trial, NCT07346495, is active but not recruiting healthy Chinese participants.
Yes, LY3372993 is also known as Remternetug. In clinical trial NCT07346495, the study is titled 'A Study of Remternetug (LY3372993) in Healthy Chinese Participants,' confirming that both names refer to the same investigational drug.